NCT05477407View on ClinicalTrials.gov

Adipose Tissue After Switch to Doravirine

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

March 15, 2024

Study Completion Date

January 1, 2025

Conditions
HIV Infections
Interventions
DRUG

Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine

Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)

Trial Locations (1)

75013

Christine Katlama, Paris

All Listed Sponsors
lead

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

OTHER